Ministry of Food and Drug Safety to check travel and overseas payment records
Strengthens crackdown on illegal resale of Mounjaro and similar drugs

The Ministry of Food and Drug Safety (MFDS) said that customs clearance may be suspended under relevant laws if obesity treatments such as Mounjaro exceed the permitted limit or are brought into the country repeatedly.

Customs officials demonstrate inspecting travel bags at the inspection counters in the arrivals hall of Terminal 1 at Incheon International Airport. File photo unrelated to this article. July 22, 2026. Photo by Kang Jinhyeong.

Customs officials demonstrate inspecting travel bags at the inspection counters in the arrivals hall of Terminal 1 at Incheon International Airport. File photo unrelated to this article. July 22, 2026. Photo by Kang Jinhyeong.

View original image

On November 18, the MFDS addressed concerns that allowing people to carry therapeutic medicines into South Korea for personal use would lead to a sharp increase in overseas prescriptions, saying, "Repeated importation is not consistent with the purpose of self-treatment."


It added, "The Korea Customs Service plans to determine whether medicines are being brought in repeatedly by considering factors such as the frequency of international travel, recent inspection history, and overseas payment records. To prevent the resale in South Korea of medicines brought in from abroad, it will conduct intensive inspections, including online, and impose strict penalties for illegal activities, using measures such as the MFDS's special judicial police when violations are identified."


The MFDS also stressed that people may have difficulty obtaining legal protection if they suffer harm, such as adverse effects, from medicines brought in from abroad, and advised, "Under the Pharmaceutical Affairs Act, compensation for harm is available only for medicines manufactured in South Korea or approved for import. Medicines carried in for personal use may not be covered by legal protections if harm occurs, so they should be prescribed and purchased abroad only when necessary and in limited quantities."


It also noted that people should receive clear instructions on storage conditions when they are prescribed medicines abroad.


On November 12, the MFDS and the Korea Customs Service began allowing people to carry into South Korea, for personal treatment, medicines such as glucagon-like peptide-1 (GLP-1) obesity treatments that were properly prescribed and purchased abroad. The general limit is six boxes, but even if that limit is exceeded, people may bring in up to a three-month supply based on the medicine's dosage instructions. Since obesity treatments such as Mounjaro and Wegovy are administered once a week, up to 12 pens may be brought in.


Some are concerned that more people will obtain prescriptions for obesity drugs in Japan, China, and elsewhere and bring them into South Korea, since drugs that sell for around 300,000 won per month in South Korea can be bought in Japan for around 100,000 won. Even including round-trip airfare, buying them in Japan is more economical. Japan has lowered the prices of obesity treatments by about 25% through drug price adjustments, and they are covered by insurance. In contrast, these treatments are classified as non-covered in South Korea, creating a substantial price gap.



Medical professionals have voiced concern that safety issues, including the misuse and overuse of medicines, could arise, and say that specific management standards to prevent such misuse and overuse are urgently needed.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing